Navigating Relapse as a Multiple Myeloma Patient

Financial Navigation Programs Are 'Efficient' for Some With Multiple ...

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better.

Multiple Myeloma - Journal of Oncology Navigation & Survivorship

REGN5458, a BCMAxCD38 bispecific antibody, demonstrated early durable responses with a tolerable safety profile and low rates of CRS in patients with relapsed/ ...

Treatment Options for Patients With Heavily Pretreated Relapsed ...

Multiple myeloma (MM) accounts for approximately 10% of hematological malignancies and 2.1% of all cancer deaths.1, 2, 3 Currently, the approved treatments for ...

Navigating the Changing Multiple Myeloma Treatment Landscape

As a single-agent in Phase I studies of twice-weekly and once-weekly dosing in heavily pretreated MM patients with relapsed/refractory disease, ...

What Does Relapsed/Refractory Multiple Myeloma Mean?

Because there is no cure for multiple myeloma at this time, all patients are estimated to reach the relapsed/refectory stage.

CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI

... multiple myeloma. Despite the excitement around these therapies ... The ability to give patients multiple doses, she reported, has led ...

Multiple myeloma - Symptoms and causes - Mayo Clinic

Multiple myeloma treatment isn't always needed right away. If the multiple myeloma is slow growing and isn't causing symptoms, close watching ...

Recent breakthroughs expand treatment options for multiple myeloma

Up to 50 per cent of patients with advanced or high-risk multiple myeloma experience relapse in less than three years and less than 30 per cent ...

Doctor Explains the Symptoms of Multiple Myeloma Relapse

Listen in as a doctor explains the multiple myeloma relapse and remission cycle and the initial symptoms of relapse to watch out for.

Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P ...

... patients on this trial needed because P-BCMA-ALLO1 was available right away.” Patients with relapsed/refractory (r/r) multiple myeloma (MM) ...

A single center retrospective study on real world CAR T-cell therapy

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and multiple myeloma have poor outcomes.

View of Roundtable discussion: Navigating challenging treatment ...

SPECIAL SUPPLEMENTJuly 2023ROUNDTABLE DISCUSSION: NAVIGATING CHALLENGING TREATMENT DECISIONS IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)Martha ...

myCME: Free Online CME & CE for Physicians, NPs, PAs and more

Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies. Ophthalmology ...

Pipeline - AstraZeneca

Rare Disease; Vaccine & Immune therapies; Other. Latest quarterly updates. Our ... AZD0305 relapsed/refractory multiple myeloma. AZD0305 - Phase I. Close.

A Podcast Series from the Multiple Myeloma Research Foundation

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.

9 Treatment Options for Myeloma Relapse | MyMyelomaTeam

After you receive a multiple myeloma diagnosis, first-line therapies are used to control the cancer and help you achieve remission.

GSK hails survival results in blood cancer patients with Blenrep

... patients with relapsed/refractory multiple myeloma. This is a ... navigation, analyse site usage, and assist in our marketing efforts.

Innovative Treatments To Compete In Growing Multiple Myeloma ...

This evolving landscape of therapies presents opportunities for pharmaceutical companies to focus on developing more effective and patient- ...

GSK's Blenrep Set For Comeback After Overall Survival Win - Citeline

Blenrep improved overall survival in the DREAMM-7 study in multiple myeloma patients ... relapsed/refractory multiple myeloma patients compared ...

Recent Treatment Advances for Relapsed Multiple Myeloma

Treatment for relapsed multiple myeloma has been advancing rapidly, including several new FDA approvals and combination therapies.